# A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism

> **NCT01441804** · PHASE3 · UNKNOWN · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Peginterferon alfa2a
- **DRUG:** Ribavirin
- **DRUG:** Peginterferon alfa2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01441804
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2013-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01441804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01441804, "A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01441804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*